GlassScriptPhysician profile
Jennifer Jane Semore
NPI 1558523415
$4,568.98
in general payments reported to CMS, 2019-2025
31 companies · $887 in 2025
The $887 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $109 · 2021: $13.14 · 2022: $630 · 2023: $1,195 · 2024: $827 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,837 · Education: $72.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,836.61 |
| Education | $72.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $791.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $594.41 | 2019-2025 | |
| Abbvie INC. | $461.46 | 2022-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $383.24 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $353.51 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.94 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Novo Nordisk INC | $273.16 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $262.65 | 2019-2024 | M-M-R II, Vaxelis, Gardasil 9 |
| Astellas Pharma US INC | $225.55 | 2019-2025 | Veozah |
| Amgen INC. | $208.53 | 2019-2024 | Prolia, Evenity, Repatha |
| Sumitomo Pharma America, INC. | $75.70 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $66.79 | 2022 | |
| Exact Sciences Corporation | $63.15 | 2023-2025 | Cologuard Collection Kit |
| Nalpropion Pharmaceuticals LLC | $57.12 | 2019 | |
| Abbott Laboratories | $47.84 | 2023-2025 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $45.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.72 | 2019-2024 | Xifaxan |
| Edwards Lifesciences Corporation | $34.49 | 2023 | |
| Sanofi-Aventis U.S. LLC | $34.19 | 2022-2023 | |
| Sanofi Pasteur INC. | $30.63 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.83 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $28.78 | 2022-2023 | |
| Sobi, INC | $25.87 | 2023 | |
| Shire North American Group INC | $20.71 | 2019 | |
| Gilead Sciences, INC. | $17.08 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.57 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2019 | |
| Rare Disease Therapeutics, INC. | $14.86 | 2025 | Xromi |
| Currax Pharmaceuticals LLC | $14.37 | 2022 | |
| Dexcom, INC. | $13.14 | 2021 | |
| Genentech USA, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Semore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.